Representatives from Ariad and its reported suitors would not discuss the market frenzy or the Mail’s report, citing longstanding company policies.
“We don’t comment on rumors and speculation,” said Ariad spokeswoman Liza Heapes.
“It is our policy at Lilly not to comment on market rumors or deal speculation,” said Mark Taylor, a spokesman for Eli Lilly.
Shire and GlaxoSmithKline similarly declined to talk about whether they were interested in Ariad.
www.bostonglobe.com/business/2014/01/23/...Vy2PvfMM/story.html